{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:45:48Z","timestamp":1791395148816,"version":"4.3.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T00:00:00Z","timestamp":1458777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1245\/s10434-016-5101-y","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T10:41:48Z","timestamp":1458816108000},"page":"2610-2617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":139,"title":["Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma"],"prefix":"10.1245","volume":"23","author":[{"given":"Faiz","family":"Gani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraja","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhree","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feriyl","family":"Bhaijjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,24]]},"reference":[{"key":"5101_CR1","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268\u201389.","journal-title":"J Hepatol."},{"key":"5101_CR2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jamcollsurg.2008.09.007","volume":"208","author":"M Aljiffry","year":"2009","unstructured":"Aljiffry M, Abdulelah A, Walsh M, et al. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 2009;208:134\u201347.","journal-title":"J Am Coll Surg."},{"key":"5101_CR3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-2004-828889","volume":"24","author":"Y Shaib","year":"2004","unstructured":"Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115\u201325.","journal-title":"Semin Liver Dis."},{"key":"5101_CR4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2003.11.030","volume":"40","author":"YH Shaib","year":"2004","unstructured":"YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40:472\u20137.","journal-title":"J Hepatol."},{"key":"5101_CR5","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med."},{"key":"5101_CR6","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med."},{"key":"5101_CR7","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064\u201374.","journal-title":"Clin Cancer Res."},{"key":"5101_CR8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejca.2014.12.006","volume":"51","author":"AM Schultheis","year":"2015","unstructured":"Schultheis AM, Scheel AH, Ozreti\u0107 L, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer. 2015;51:421\u20136.","journal-title":"Eur J Cancer."},{"key":"5101_CR9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43\u201351.","journal-title":"Cancer Discov."},{"key":"5101_CR10","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med."},{"key":"5101_CR11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/jso.21376","volume":"100","author":"Y Ye","year":"2009","unstructured":"Ye Y, Zhou L, Xie X, et al. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg Oncol. 2009;100:500\u20134.","journal-title":"J Surg Oncol."},{"key":"5101_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","volume":"38","author":"KC Soares","year":"2015","unstructured":"Soares KC, Rucki AA, Wu AA, et al. PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2015;38:1\u201311.","journal-title":"J Immunother."},{"key":"5101_CR13","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109\u201317.","journal-title":"Lancet."},{"key":"5101_CR14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134\u201344.","journal-title":"N Engl J Med."},{"key":"5101_CR15","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4:127ra37.","journal-title":"Sci Transl Med."},{"issue":"2","key":"5101_CR16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1158\/1078-0432.CCR-15-0715","volume":"22","author":"F Sabbatino","year":"2016","unstructured":"Sabbatino F, Villani V, Yearley JH, et al. PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res. 2016;22(2), 470\u2013478.","journal-title":"Clin Cancer Res."},{"key":"5101_CR17","unstructured":"Leyva-Illades D, McMillin M, Quinn M, et al. Cholangiocarcinoma pathogenesis: role of the tumor microenvironment. Transl Gastrointest Cancer. 2012;1:71\u201380. Retrieved 7 Sep 2015 http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3448449&tool=pmcentrez&rendertype=abstract ."},{"key":"5101_CR18","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/j.1349-7006.2010.01614.x","volume":"101","author":"H Hasita","year":"2010","unstructured":"Hasita H, Komohara Y, Okabe H, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010;101:1913\u20139.","journal-title":"Cancer Sci."},{"key":"5101_CR19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24351","volume":"54","author":"GL Tyson","year":"2011","unstructured":"Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54:173\u201384.","journal-title":"Hepatology."},{"key":"5101_CR20","unstructured":"Ramanathan S, Jagannathan N. Tumor-associated macrophage: a review on the phenotypes, traits, and functions. Iran J Cancer Prev. 2014;7:1\u20138. Retrieved 2 Sep 2015 http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=4142950&tool=pmcentrez&rendertype=abstract ."},{"key":"5101_CR21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ijc.11380","volume":"107","author":"U Liengswangwong","year":"2003","unstructured":"Liengswangwong U, Nitta T, Kashiwagi H, et al. Infrequent microsatellite instability in liver fluke infection-associated intrahepatic cholangiocarcinomas from Thailand. Int J Cancer. 2003;107:375\u201380.","journal-title":"Int J Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5101-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-016-5101-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5101-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T07:22:16Z","timestamp":1559632936000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-016-5101-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,24]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["5101"],"URL":"https:\/\/doi.org\/10.1245\/s10434-016-5101-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,24]]}}}